Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 10/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.44 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | AHR | P35869 | 1/20 | 0.40 |
| ▸ | ALPG | P10696 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | MARS1 | P56192 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4636926 | 0.78 | IDO1 (0.52) | ALPLHSP90AA1HSP90AB1KMT2ALMNA | |
| SCHEMBL9804034 | 0.73 | NOTUM (0.47) | ALPLKMT2A | |
| SCHEMBL3623272 | 0.71 | IDO1 (0.53) | MAPK1IDO1 | |
| SCHEMBL3846339 | 0.70 | ALPL (0.49) | ALPLHSP90AA1HSP90AB1MAPK1KMT2A | |
| SCHEMBL31703168 | 0.70 | ALPL (0.56) | ALPLMAPK1KMT2ALMNAALPG | |
| SCHEMBL16291358 | 0.69 | AHR (0.46) | LMNAIDO1AHR | |
| SCHEMBL29624840 | 0.68 | AHR (0.64) | HSP90AA1HSP90AB1MAPK1IDO1AHR | |
| SCHEMBL464507 | 0.68 | AHR (0.64) | HSP90AA1HSP90AB1MAPK1IDO1AHR | |
| SCHEMBL3631530 | 0.68 | HSP90AA1 (0.44) | ALPLHSP90AA1HSP90AB1MAPK1KMT2A | |
| SCHEMBL10682654 | 0.68 | ALPL (0.58) | ALPLHSP90AA1HSP90AB1MAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114457159-B | Method for detecting tumor cells or tumor cell fragments | 珠海圣美生物诊断技术有限公司 | 2023-09-19 | — | — | CN | claimed |
| CN-114085911-B | Method for detecting tumor cells or tumor cell fragments | 珠海圣美生物诊断技术有限公司 | 2022-05-17 | — | — | CN | claimed |
| CN-114457159-A | Method for detecting tumor cells or tumor cell fragments | 珠海圣美生物诊断技术有限公司 | 2022-05-10 | — | — | CN | claimed |
| CN-114085911-A | Method for detecting tumor cells or tumor cell fragments | 珠海圣美生物诊断技术有限公司 | 2022-02-25 | — | — | CN | claimed |
| US-20140371218-A1 | NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS | OGEDA SA (BE) | 2014-12-18 | — | — | US | claimed |
| CN-114457159-B | Method for detecting tumor cells or tumor cell fragments | 珠海圣美生物诊断技术有限公司 | 2023-09-19 | — | — | CN | disclosed |
| CN-114085911-B | Method for detecting tumor cells or tumor cell fragments | 珠海圣美生物诊断技术有限公司 | 2022-05-17 | — | — | CN | disclosed |
| CN-114457159-A | Method for detecting tumor cells or tumor cell fragments | 珠海圣美生物诊断技术有限公司 | 2022-05-10 | — | — | CN | disclosed |
| CN-114085911-A | Method for detecting tumor cells or tumor cell fragments | 珠海圣美生物诊断技术有限公司 | 2022-02-25 | — | — | CN | disclosed |
| CN-104136399-B | The pyrazolopyrimidine base inhibitor of ubiquitin activating enzyme | 米伦纽姆医药公司 | 2018-08-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371218-A1 | NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS | ACKR3, BDKRB2, GPR3 | ALPL 4475/4885HSP90AA1 4270/4885HSP90AB1 4002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.